ScreenerHero

SRNESorrento Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · sorrentotherapeutics.com
0.0008USD0.00%Mkt Cap: 441024 $P/E: —

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap441.02K $
Enterprise Value134.56M $
Revenue (TTM)64.27M $
Gross Profit29.39M $
Net Income (TTM)-572.84M $
Revenue/Share0.1270 USD
Last Price0.0008 USD
Fiscal Year EndDec 2022
MR QuarterJun 2023
Employees949
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-0.39
EV/Revenue2.09
P/S0.01
P/B-0.00
EPS (TTM)-0.14
EPS (Forward)—
52W Range
0.00011% of range0.0985
52W High0.0985 USD
52W Low0.0001 USD
Profitability
Gross Margin46.77%
Oper. Margin-510.93%
EBITDA Margin0.00%
Profit Margin-911.60%
ROE3078.97%
ROA-121.15%
Growth
Revenue Growth31.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-293.86M $
CapEx (TTM)13.66M $
FCF Margin-89.51%
FCF Yield-13044.53%
Net Debt126.97M $
Net Debt/EBITDA-0.37
Balance Sheet
Debt/Equity-7.23
Current Ratio0.41
Quick Ratio0.34
Book Value/Sh-0.3770 USD
Cash/Share0.1480 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 1, 2013
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.551.28M
Float539.11M
Insiders0.00%
Institutions0.06%
Short Interest
Short Ratio5.0d
Short % Float11.96%
Short % Out.11.84%
Shares Short64.56M
Short (prev mo.)61.44M
Technical
SMA 500.0008 (+5.5%)
SMA 2000.0021 (-62.5%)
Beta0.12
S&P 52W Chg18.16%
Avg Vol (30d)208.65K
Avg Vol (10d)87.54K
Technical Indicators
RSI (14)55.3
MACD-0.0000
MACD Signal-0.0001
MACD Hist.+0.0000
BB Upper0.0010 USD
BB Middle0.0006 USD
BB Lower0.0002 USD
BB Width133.92%
ATR (14)0.0013 USD
Vol Ratio (20d)1.23x